Risk factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia
- PMID: 22632455
- DOI: 10.1111/j.1553-2712.2012.01365.x
Risk factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia
Abstract
Objectives: Due to antimicrobial resistance in Streptococcus pneumoniae, national guidelines recommend a respiratory fluoroquinolone or combination antimicrobial therapy for outpatient treatment of community-acquired pneumonia (CAP) associated with risk factors for drug-resistant S. pneumoniae (DRSP). The objectives of this study were to assess the prevalence of these risk factors and antibiotic prescribing practices in cases of outpatient CAP treated in the acute care setting.
Methods: This was a retrospective cohort study of adult outpatients treated for CAP in the emergency department (ED) or urgent care center of an urban, academic medical center from May 1, 2009, through October 31, 2009, and comparison of antibiotic therapy in cases with and without DRSP risk factors.
Results: Of 175 patients, 90 (51%) had at least one DRSP risk factor, most commonly asthma (n = 28, 16%), alcohol abuse (n = 24, 14%), diabetes mellitus (n = 18, 10%), chronic obstructive pulmonary disease (n = 16, 9%), age > 65 years (n = 16, 9%), and use of antibiotics within 3 months (15, 9%). Antibiotic prescriptions were similar among cases with and without DRSP risk factors: a macrolide (62% vs. 59%, respectively, p = 0.65), doxycycline (27% vs. 28%, p = 0.82), or a respiratory fluoroquinolone (9% vs. 9%, p = 0.90). Concordance with national guideline treatment recommendations was significantly lower in cases with DRSP risk factors (9% vs. 87%, p < 0.0001).
Conclusions: DRSP risk factors were present in approximately half of outpatient CAP cases treated in the acute care setting; however, guideline-concordant antibiotic therapy was infrequent. Strict adherence to current guidelines would substantially increase use of fluoroquinolones or combination therapy. Whether the potential risks associated with these broad-spectrum regimens are justified by improved clinical outcomes requires further study.
© 2012 by the Society for Academic Emergency Medicine.
Similar articles
-
Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.Clin Ther. 2010 Feb;32(2):293-9. doi: 10.1016/j.clinthera.2010.02.006. Clin Ther. 2010. PMID: 20206787
-
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med. 2000 May 22;160(10):1399-408. doi: 10.1001/archinte.160.10.1399. Arch Intern Med. 2000. PMID: 10826451
-
Streptococcus pneumoniae: does antimicrobial resistance matter?Semin Respir Crit Care Med. 2009 Apr;30(2):210-38. doi: 10.1055/s-0029-1202939. Epub 2009 Mar 18. Semin Respir Crit Care Med. 2009. PMID: 19296420 Review.
-
Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.Clin Ther. 2008 Feb;30(2):358-71. doi: 10.1016/j.clinthera.2008.01.023. Clin Ther. 2008. PMID: 18343274
-
Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.J Lab Clin Med. 2004 May;143(5):269-83. doi: 10.1016/j.lab.2004.02.002. J Lab Clin Med. 2004. PMID: 15122171 Review.
Cited by
-
Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review.J Clin Med. 2023 Oct 30;12(21):6864. doi: 10.3390/jcm12216864. J Clin Med. 2023. PMID: 37959328 Free PMC article. Review.
-
Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial.Front Med (Lausanne). 2023 Jul 28;10:1225710. doi: 10.3389/fmed.2023.1225710. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37575994 Free PMC article.
-
Community-Acquired Pneumonia.Emerg Med Clin North Am. 2018 Nov;36(4):665-683. doi: 10.1016/j.emc.2018.07.001. Epub 2018 Sep 6. Emerg Med Clin North Am. 2018. PMID: 30296998 Free PMC article. Review.
-
Antibiotic Resistant Superbugs: Assessment of the Interrelationship of Occurrence in Clinical Settings and Environmental Niches.Molecules. 2016 Dec 27;22(1):29. doi: 10.3390/molecules22010029. Molecules. 2016. PMID: 28035988 Free PMC article. Review.
-
Combination therapy with ampicillin and azithromycin in an experimental pneumococcal pneumonia is bactericidal and effective in down regulating inflammation in mice.J Inflamm (Lond). 2014 Feb 24;11(1):5. doi: 10.1186/1476-9255-11-5. J Inflamm (Lond). 2014. PMID: 24565171 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
